Japan’s First! A Complete Guide to “Alli” – The First Medication to Reduce Visceral Fat: Effects, Side Effects, and Evidence

On April 8, 2024, “Alli,” Japan’s first drug aimed at reducing visceral fat, was released. Visceral fat is known to increase the risk of lifestyle-related diseases and has been a challenging issue for those who could not reduce it through exercise or dietary measures alone. “Alli” has been eagerly awaited as a solution. However, many questions arise: Is “Alli” truly effective? What are the side effects? Who can take it? Let’s dive deep into the details of “Alli.” What is Alli? Overview of Alli Alli, developed and sold by Taisho Pharmaceutical, is a medication designed to reduce visceral fat. Its active ingredient, Orlistat, blocks the absorption of fats, thus reducing visceral fat, waist circumference, and body weight. Orlistat is approved in over 100 countries globally and is established for its safety and efficacy. Although previously available only as a prescription drug in Japan, it has now been released as an over-the-counter medication for the first time. Effects of Alli Alli can block about 25-30% of fat absorption from your diet. The expected benefits include: In clinical trials, those taking Alli lost on average more than twice as much weight compared to those who took a placebo. Specifically, the placebo group […]

A New Hope in Treatment: The Potential of Kyoto University’s “Tooth Growth Medication”

Overview and Clinical Trial Plans for the Tooth Growth Medication In 2024, a medical startup originating from Kyoto University is progressing in the development of a revolutionary “tooth growth medication.” This medication promises hope to individuals suffering from congenital anodontia, a condition where permanent teeth do not develop. Research Background Congenital anodontia often results from issues with bone morphogenetic proteins (BMP) and a molecule called USAG-1. The medication works by inhibiting the activity of USAG-1, aiding the development of tooth germs (tooth buds), and thus promoting the growth of missing teeth. Results from Animal Experiments In animal trials, neutralizing antibodies were administered to mice, beagles, and ferrets, demonstrating tooth growth in areas previously lacking teeth. Based on these outcomes, clinical trials on humans are scheduled to begin in September 2024, aiming to develop a treatment for congenital anodontia. The Path to Clinical Trials From September 2024, the plan is to conduct human clinical trials. The startup has already received numerous inquiries from patients eager to participate, reflecting high social expectations for this treatment. If successful, this innovative treatment could significantly improve the lives of many patients and profoundly impact the future of dental care. The History and Details of Tooth […]